These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 36226535)

  • 1. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches.
    Gu T; Zhu M; Huang H; Hu Y
    J Zhejiang Univ Sci B; 2022 Oct; 23(10):793-811. PubMed ID: 36226535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involving stemness factors to improve CAR T-cell-based cancer immunotherapy.
    Noraldeen SAM; Rasulova I; Lalitha R; Hussin F; Alsaab HO; Alawadi AH; Alsaalamy A; Sayyid NH; Alkhafaji AT; Mustafa YF; Shayan SK
    Med Oncol; 2023 Oct; 40(11):313. PubMed ID: 37779152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
    Tahmasebi S; Elahi R; Esmaeilzadeh A
    Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.
    Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H
    Front Immunol; 2022; 13():887471. PubMed ID: 35935930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies.
    Marhelava K; Krawczyk M; Firczuk M; Fidyt K
    Cells; 2022 May; 11(11):. PubMed ID: 35681499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma.
    Cai F; Zhang J; Gao H; Shen H
    Eur J Haematol; 2024 Feb; 112(2):223-235. PubMed ID: 37706523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies.
    Huang J; Huang X; Huang J
    Front Immunol; 2022; 13():1019115. PubMed ID: 36248810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
    Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
    Front Immunol; 2022; 13():927153. PubMed ID: 35757715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy.
    Li W; Pan X; Chen L; Cui H; Mo S; Pan Y; Shen Y; Shi M; Wu J; Luo F; Liu J; Li N
    Front Immunol; 2023; 14():1186383. PubMed ID: 37342333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
    Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
    Front Immunol; 2022; 13():871661. PubMed ID: 35911706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy.
    Dreyzin A; Rankin AW; Luciani K; Gavrilova T; Shah NN
    Expert Rev Clin Immunol; 2024 Jul; 20(7):745-763. PubMed ID: 38739466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
    Lindo L; Wilkinson LH; Hay KA
    Front Immunol; 2020; 11():618387. PubMed ID: 33643299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies.
    Zhang X; Zhang H; Lan H; Wu J; Xiao Y
    Front Immunol; 2023; 14():1101495. PubMed ID: 36891310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
    Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
    Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
    Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
    Gumber D; Wang LD
    EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theranostic chimeric antigen receptor (CAR)-T cells: Insight into recent trends and challenges in solid tumors.
    Kheyrolahzadeh K; Tohidkia MR; Tarighatnia A; Shahabi P; Nader ND; Aghanejad A
    Life Sci; 2023 Sep; 328():121917. PubMed ID: 37422069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-T Therapies in Solid Tumors: Opportunities and Challenges.
    Guzman G; Reed MR; Bielamowicz K; Koss B; Rodriguez A
    Curr Oncol Rep; 2023 May; 25(5):479-489. PubMed ID: 36853475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.